Inhibitory effect of epigallocatechin gallate (EGCG), resveratrol, and curcumin on proliferation of human retinal pigment epithelial cells in vitro

Current Eye Research

Volumn 35, Issue 11, 2010, Pages 1021-1033

  Alex, Anne F ^a,b   Spitznas, Manfred ^a   Tittel, André P ^a   Kurts, Christian ^a   Eter, Nicole ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Apoptosis; Carboxyfluorescein succinimidyl ester; Curcumin; Epigallocatechin gallate; Proliferation; Resveratrol; Retinal pigment epithelial cells

Indexed keywords

ANTIMITOTIC AGENT; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CASPASE 3; CASPASE 7; CASPASE 8; CURCUMIN; EPIGALLOCATECHIN GALLATE; RESVERATROL;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PIGMENT EPITHELIUM; PRIORITY JOURNAL;

ANTIOXIDANTS; APOPTOSIS; CASPASES; CATECHIN; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CURCUMIN; FLOW CYTOMETRY; HUMANS; NECROSIS; RETINAL PIGMENT EPITHELIUM; STILBENES;

EID: 77958515319     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.506970     Document Type: Article

References (69)

1. Tsuboi S. Measurement of the volume flow and hydraulic conductivity across the isolated dog retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1987;28:1776-1782.
2. Bosch E, Horwitz J, Bok D. Phagocytosis of outer segments by retinal pigment epithelium: Phagosome-lysosome interaction. J Histochem Cytochem. 1993;41:253-263.
3. Machemer R. Proliferative vitreoretinopathy (PVR): A personal account of its pathogenesis and treatment. Proctor lecture. Invest Ophthalmol Vis Sci. 1988;29:1771-1783.
4. Hiscott P, Sheridan C, Magee RM, et al. Matrix and the retinal pigment epithelium in proliferative retinal disease. Progr Retin Eye Res. 1999;18:167-190.
5. Stodtler M, Mietz H, Wiedemann P, et al. Immunohistochemistry of anterior proliferative vitreoretinopathy. Report of 11 cases. Intl Ophthalmol. 1994;18:323-328.
6. Hiscott P, Gray R, Grierson I, et al. Cytokeratin-containing cells in proliferative diabetic retinopathy membranes. Br J Ophthalmol. 1994;78:219-222.
7. Takano S, Ishiwata S, Nakazawa M, et al. Determination of ascorbic acid in human vitreous humor by high-performance liquid chromatography with UV detection. Curr Eye Res. 1997;16:589-594.
8. Burke JM, Foster SJ. Induction of DNA synthesis by co-culture of retinal glia and pigment epithelium. Invest Ophthalmol Vis Sci. 1985;26:636-642.
9. Cheema RA, Peyman GA, Fang T, et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthal Surg, Lasers & Imag. 2007;38:365-370.
10. Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1996;37:2318-2325.
11. Yasukawa T, Kimura H, Dong J, et al. Effect of tranilast on proliferation, collagen gel contraction, and transforming growth factor beta secretion of retinal pigment epithelial cells and fibroblasts. Ophthalmic Res. 2002;34:206-212.
12. Krott R, Lebek J, Grisanti S, et al. Antiproliferative effect of genistein on cultured retinal pigment epithilial cells of the pig. Intl J Ophthalmol. 2000;214:296-300.
13. Koutsandrea CN, Miceli MV, Peyman GA, et al. Ciprofloxacin and dexamethasone inhibit the proliferation of human retinal pigment epithelial cells in culture. Curr Eye Res. 1991;10:249-258.
14. Wu WC, Hu DN, Mehta S, et al. Effects of retinoic acid on retinal pigment epithelium from excised membranes from proliferative vitreoretinopathy. J Ocular Pharmacol Therapeut. 2005;21:44-54.
15. Mojon D, Boscoboinik D, Haas A, et al. Vitamin E inhibits retinal pigment epithelium cell proliferation in vitro. Ophthalmic Res. 1994;26:304-309.
16. Handa JT, Murad S, Jaffe GJ. Inhibition of cultured human RPE cell proliferation and lysyl hydroxylase activity by hydroxy derivatives of minoxidil. Invest Ophthalmol Vis Sci. 1994;35:463-469.
17. Gao Q, Ge J. The inhibition of CA2+ influx induced by hypericin in cultured human retinal pigment epithelial cells analyzed by confocal imaging. Ophthalmic Res. 2005;37:128-135.
18. Yoo JS, Sakamoto T, Spee C, et al. cis-Hydroxyproline inhibits proliferation, collagen synthesis, attachment, and migration of cultured bovine retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1997;38:520-528.
19. Schmidt JF, Loeffler KU. Toxicity and antiproliferative effect of aclacinomycin A on RPE cells in vitro. Curr Eye Res. 1996;15:1112-1116.
20. Wang YS, Hui YN, Wiedemann P. Role of apoptosis in the cytotoxic effect mediated by daunorubicin in cultured human retinal pigment epithelial cells. J Ocular Pharmacol Therapeut. 2002;18:377-387.
21. Steinhorst UH, Chen EP, Machemer R, et al. N,Ndimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: Efficacy and toxicity on the rabbit retina. Exper Eye Res. 1993;56:489-495.
22. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev. 2006;5:493-506.
23. Friedman M. Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutri Food Res. 2007;51:116-134.
24. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exper Med Biol. 2007;595:471-480.
25. D'Incalci M, Steward WP, Gescher AJ. Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol. 2005;6:899-904.
26. Toda M, Okubo S, Ikigai H, et al. [Antibacterial and anti-hemolysin activities of tea catechins and their structural relatives]. Nippon Saikingaku Zasshi 1990;45:561-566.
27. Lin YL, Lin JK. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol. 1997;52:465-472.
28. Maeda-Yamamoto M, Inagaki N, Kitaura J, et al. O-methylated catechins from tea leaves inhibit multiple protein kinases in mast cells. J Immunol. 2004;172:4486-4492.
29. Wheeler DS, Catravas JD, Odoms K, et al. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutri. 2004;134:1039-1044.
30. Yang F, Oz HS, Barve S, et al. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol. 2001;60:528-533.
31. Brown MD. Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer. Altern Med Rev. 1999;4:360-370.
32. Ahn HY, Hadizadeh KR, Seul C, et al. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol Biol Cell. 1999;10:1093-1104.
33. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature. 1999;398:381.
34. Jung YD, Kim MS, Shin BA, et al., EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer. 2001;84:844-850.
35. Das S, Alagappan VK, Bagchi D, et al. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: A potential mechanism for resveratrol preconditioning of the heart. Vasc Pharmacol. 2005;42:281-289.
36. Park SY, Jeong KJ, Lee J, et al. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: Their inhibition by resveratrol. Cancer Lett. 2007;258:63-69.
37. Zhang Q, Tang X, Lu QY, et al. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1-alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Therapeut. 2005;4:1465-1474.
38. Yoysungnoen P, Wirachwong P, Bhattarakosol P, et al. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc. 2006;34:109-115.
39. Kim YS, Ahn Y, Hong MH, et al. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovas Pharmacol. 2007;50:41-49.
40. Shankar S, Ganapathy S, Chen Q, et al. Curcumin sensitizes TRAIL-resistant xenografts: Molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer. 2008;7:16.
41. Cholujova D, Jakubikova J, Kubes M, et al. Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology. 2008;213:629-640.
42. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Meth. 1990;133:87-97.
43. Berardi V, Ricci F, Castelli M, et al. Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: Potential clinical use. J Exper Clin Cancer Res. 2009;28:96.
44. Dunn KC, Aotaki-Keen AE, Putkey FR, et al. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exper Eye Res. 1996;62:155-169.
45. Bai Y, Mao QQ, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010 101:488-493.
46. Parish CR. Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol. 1999;77:499-508.
47. Mintern J, Li M, Davey GM, et al. The use of carboxyfluorescein diacetate succinimidyl ester to determine the site, duration and cell type responsible for antigen presentation in vivo. Immunol Cell Biol. 1999;77:539-543.
48. Scoltock AB, Cidlowski JA. Activation of intrinsic and extrinsic pathways in apoptotic signaling during UV-C-induced death of Jurkat cells: The role of caspase inhibition. Exper Cell Res. 2004;297:212-223.
49. King RE, Kent KD, Bomser JA. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chemico-Biol Interac. 2005;151:143-149.
50. Premanand C, Rema M, Sameer MZ, et al. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest Ophthalmol Vis Sci. 2006;47:2179-2184.
51. Yang SW, Lee BR, Koh JW. Protective effects of epigallocatechin gallate after UV irradiation in cultured human retinal pigment epithelial cells. Korean J Ophthalmol. 2007;21:232-237.
52. Ueda T, Ueda T, Armstrong D. Preventive effect of natural and synthetic antioxidants on lipid peroxidation in the mammalian eye. Ophthal Res. 1996;28:184-192.
53. Hanneken A, Lin FF, Johnson J, et al. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci. 2006;47:3164-3177.
54. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: Molecular mechanisms and therapeutic potential. Frontiers Biosci. 2007;12:4839-4854.
55. Formigli L, Papucci L, Tani A, et al. Aponecrosis: Morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol. 2000;182:41-49.
56. Cho YS, Park SY, Shin HS, et al. Physiological consequences of programmed necrosis, an alternative form of cell demise. Molec Cells. 29:327-332.
57. Asaria RH, Charteris DG. Proliferative vitreoretinopathy: Developments in pathogenesis and treatment. Comp Ophthalmol Update. 2006;7:179-185.
58. Pastor JC. Proliferative vitreoretinopathy: An overview. Survey Ophthalmol. 1998;43:3-18.
59. Sebag J. Shaken not stirred. Ophthalmology. 2001;108:1177-1178.
60. Kim IK, Arroyo JG. Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clinics North America. 2002;15:81-86.
61. Yang P, Peairs JJ, Tano R, et al. Caspase-8-mediated apoptosis in human RPE cells. Invest Ophthalmol Vis Sci. 2007;48:3341-3349.
62. Yang CS, Chen L, Lee MJ, et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidem, Biomark Preven. 1998;7:351-354.
63. De Santi C, Pietrabissa A, Spisni R, et al. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica; Fate Foreign Comp Biol Sys. 2000;30:609-617.
64. Sale S, Verschoyle RD, Boocock D, et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4 tetramethoxystilbene. Br J Cancer. 2004;90:736-744.
65. Vitrac X, Desmouliere A, Brouillaud B, et al. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003;72:2219-2233.
66. Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: Problems and promises. Mol Pharmaceut. 2007;4:807-818.
67. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895-2900.
68. Lao CD, Ruffin MT, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
69. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64:353-356.